Packaged Foods and Meats

WAI CHUN BIOTEC

WAI CHUN BIOTEC released FY2026 Q1 earnings on February 27 (BJT), actual revenue HKD 176.08 M, actual EPS HKD -0.0166

WAI CHUN BIOTEC released FY2026 Semi-Annual Earnings on February 27 After-Market (BJT), actual revenue HKD 352.15 M, actual EPS HKD -0.0332

WAI CHUN BIOTEC released FY2026 Q2 earnings on February 27 After-Market BJT, actual revenue HKD 176.08 M, actual EPS HKD -0.0166

WAI CHUN BIOTEC FY2026 Semi-Annual Earnings Release on February 27, 2026 (BJT)

Waijun Biotechnology Provides Unsecured Loan Violating Listing Rules and Takes Rectification Measures

WAI CHUN BIOTEC released FY2025 Q3 earnings on September 30 (BJT), actual revenue HKD 108.06 M, actual EPS HKD -0.0027

WAI CHUN BIOTEC released FY2025 9 Months Earnings on September 30 (BJT), actual revenue HKD 269.11 M, actual EPS HKD -0.0824

WAI CHUN BIOTEC released FY2025 Annual Earnings on September 30, 2025 (BJT), with actual revenue of HKD 377.17 M and EPS of HKD -0.0843

WAI CHUN BIOTEC released FY2025 Q4 earnings on September 30 (BJT), actual revenue HKD 108.06 M, actual EPS HKD -0.0027

Wai Chun Biotechnology Expected Net Loss to Significantly Decrease in FY2025

WAI CHUN BIOTEC to Release FY2025 Annual Earnings on September 30, 2025 (BJT)

Wai Jun Biotech Grants Stock Options

Weijun Biotechnology Issues New Convertible Bonds to Improve Financial Condition

Wei Jun Biotechnology to issue 7 million shares on March 20, 2025, due to the conversion of convertible bonds amounting to HKD 1.75 million

WAI CHUN BIOTEC released FY2025 Q1 earnings on February 28 (BJT), actual revenue 80.53 M HKD, actual EPS -0.0398 HKD

Weijun Biotechnology Releases Interim Results for 2024, Revenue Decreases by 15.38%

WAI CHUN BIOTEC released FY2025 Semi-Annual Earnings on February 28 After-Market (BJT), with actual revenue of 161.06 M HKD and EPS of -0.0796 HKD

WAI CHUN BIOTEC released FY2025 Q2 earnings on February 28 After-Market (BJT), actual revenue 80.53 M HKD, actual EPS -0.0398 HKD

WAI CHUN BIOTEC to Release FY2025 Semi-Annual Earnings on February 28, 2025 (BJT)

WAI CHUN BIOTEC released FY2024 Q4 earnings on December 20 (BJT) with actual revenue of 89.87 M HKD and EPS of -0.1092 HKD

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

00660

WAI CHUN BIOTEC fell 11.90%; Mengniu Dairy fell 1.41%, with a transaction amount of HKD 131 million; WH Group fell 0.56%, with a transaction amount of HKD 91.91 million; Tingyi (Cayman Islands) Holding Corp fell 1.81%, with a transaction amount of HKD 56.21 million; Muyuan Foods fell 1.07%, with a market value of HKD 245.6 billion

HK Stock Alerts

Hong Kong Stock Movement: WAI CHUN BIOTEC's stock price soared 400% after resuming trading, but insider information has caused market uncertainty, leading to a decline of 11.90%

159849

516930

159837

Wai Chun Bio-Technology Ltd. has requested a one-day trading halt on the Hong Kong Stock Exchange, effective from 9:00 a.m. on 13 April 2026, pending the release of an announcement containing inside information. This indicates a potentially material development for shareholders and market participants. Investors are awaiting clarity on how this undisclosed matter may impact the company's operations, governance, or financial outlook. Wai Chun Bio-Technology is a Hong Kong-listed company with a market cap of HK$45.51M, led by Chairman and CEO Lam Ka Chun.

Tip Ranks

China Merchants CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

E Fund CSI Biotechnology Theme ETF

Wai Chun Bio-Technology Halts Trading Pending Inside Information Announcement

513120

06826

520500

516500

Hong Kong Stock Exchange filings show that Wuhan Bin Hui Biological Technology Co., Ltd. - B has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International, China Merchants Securities International, and BOCI Asia Limited as joint sponsors

Wallstreetcn

GF CSI HK Innovative Drugs Industry ETF(QDII)

HAOHAI BIOTEC

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

GREEN FRESH BIO

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC CSI Biotechnology Theme ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Bin Hui Biotechnology Submits Listing Application to Hong Kong Stock Exchange

Wai Chun Bio-Technology Reschedules EGM and Adjusts Book Closure Dates

Wai Chun Bio-Technology Reschedules EGM and Adjusts Book Closure Dates

WAI CHUN BIOTEC announced its interim results for the six months ending December 2025, with revenue of HKD 352 million, an increase of 118.7% year-on-year. The loss narrowed from HKD 13.66 million in the same period last year to HKD 5.94 million, with a loss per share of HKD 0.0333. No dividend is declared

AASTOCKS

"Performance" WAI CHUN BIOTEC's mid-term loss narrowed to 5.94 million yuan

01013

WAI CHUN GROUP and WAI CHUN BIOTEC are required to each pay HKD 2.67 million plus interest and legal fees due to a ruling by the Hong Kong High Court, believing that the plaintiff's claim amount is excessive, and have filed an appeal. The ruling involves 50% of the intermediate income, rent, and related expenses for the property located on the 13th floor of Tower 2, Harbour Centre, Hong Kong, from September 2022 to April 2023

WAI CHUN GROUP

WAI CHUN GROUP's WAI CHUN BIOTEC has appealed the court ruling

WAI CHUN BIOTEC(00660.HK)

Hong Kong Stock Movement: WAI CHUN BIOTEC's stock price soared 400% after resuming trading, but insider information has caused market uncertainty, leading to a decline of 11.90%

Wai Chun Bio-Technology Halts Trading Pending Inside Information Announcement

Bin Hui Biotechnology Submits Listing Application to Hong Kong Stock Exchange

Wai Chun Bio-Technology Reschedules EGM and Adjusts Book Closure Dates

"Performance" WAI CHUN BIOTEC's mid-term loss narrowed to 5.94 million yuan

WAI CHUN GROUP's WAI CHUN BIOTEC has appealed the court ruling